Hyperhidrosis

Hyperhidrosis is a disorder of excessive sweating beyond what is needed for normal thermoregulation, affecting an estimated 3% of the population — roughly 950,000 Canadians, of whom about 300,000 have a severe form.^[1] It splits into two clinically distinct patterns that this chapter treats very differently. Primary focal hyperhidrosis is by far the most common presentation pharmacists see: bilateral, relatively symmetric, excessive sweating localized to one or more of the axillae, palms, soles, or face/craniofacial region, with no identifiable underlying medical cause.^[2] It typically begins in childhood or adolescence (facial sweating can start somewhat later) and — a genuinely useful clinical clue — does not occur during sleep, since it is driven by overactive sympathetic cholinergic signalling to structurally normal eccrine sweat glands rather than by any systemic process.^[3][1] Secondary generalized hyperhidrosis, in contrast, involves the whole body, commonly does occur during sleep, and is driven by an identifiable underlying medical condition, medication, or substance exposure (see Risk Factors).^[3][2] Distinguishing these two patterns — not simply confirming "excessive sweating" in general — is the first and most consequential step in this chapter.

Primary focal hyperhidrosis — the presentation pharmacists see most often

Primary focal hyperhidrosis accounts for the large majority of hyperhidrosis presentations and follows a recognizable pattern: excessive sweating that is bilateral and relatively symmetric, confined to one or more of the axillae, palms, soles, or face/scalp, begins before age 25 in most patients (commonly in childhood or adolescence), occurs at least weekly, impairs daily activities, and — the single most useful distinguishing feature at the bedside — stops during sleep.^[2][3] A positive family history is common, reported in roughly two-thirds of patients, consistent with a genetic predisposition.^[1][3] Formal criteria (below, in Assessment & Diagnosis) require focal, visible, excessive sweating present for six months or longer plus at least two of these features.^[2]

Secondary generalized hyperhidrosis — a different pattern entirely

Secondary hyperhidrosis is sweating caused by, or occurring as a symptom of, an underlying medical condition or a medication — see Risk Factors for the specific screening list.^[5] It is typically generalized rather than confined to the classic focal sites, frequently does occur during sleep (night sweats), and often has an adult onset with no personal or family history of the childhood-pattern primary disease.^[2][3] A patient presenting with new, whole-body sweating — particularly with sleep involvement or accompanying systemic symptoms — should be evaluated for a secondary cause rather than started on primary-hyperhidrosis therapy (see Red Flags & Refer).

Before labelling a patient's sweating as primary focal hyperhidrosis, it is worth actively screening for the secondary causes below — this is squarely within a pharmacist's scope through a careful history and medication review, and it changes management entirely if found.

• A positive family history — reported in roughly two-thirds of primary focal hyperhidrosis patients, consistent with a genetic predisposition; this supports (but does not by itself confirm) a primary diagnosis.^[1][3]
• Hyperthyroidism (thyrotoxicosis) — a well-recognized endocrine cause of secondary generalized hyperhidrosis; screening thyroid-stimulating hormone is reasonable when the history suggests it.^[2][5]
• Menopause — vasomotor symptoms and hot flashes are a very common cause of new-onset generalized sweating in this population.^[2][5]
• Diabetes mellitus, through autonomic dysfunction, hypoglycemia, and, in some patients, a specific gustatory sweating pattern — diabetes is consistently listed among the endocrine causes of secondary hyperhidrosis.^[2][6]
• Acute or chronic infection and fever — active infectious or febrile illness is a recognized driver of secondary sweating and should prompt a directed history (fevers, weight loss, night sweats, localizing symptoms).^[6]
• Medications — a genuinely important, pharmacist-relevant category. SSRIs are a well-documented cause of drug-induced hyperhidrosis, alongside other psychiatric medications including tricyclic antidepressants, SNRIs, and antipsychotics.^[2][5] Other reported drug causes include insulin and sulfonylureas (via hypoglycemia), tamoxifen and raloxifene, sildenafil, and niacin.^[2]
• Opioid withdrawal — withdrawal from an opioid (or another addictive substance such as alcohol or cocaine) is a recognized cause of secondary sweating, alongside other high-sympathetic-discharge states such as severe pain or cardiovascular shock.^[5][6]
• Malignancy (including lymphoma) and other high-sympathetic-discharge or neurologic states — less common, but part of the broader secondary differential when the pattern or associated symptoms do not fit primary focal disease.^[6]

Diagnosis is clinical, not laboratory-based, for typical primary disease

No laboratory test or biopsy is required to diagnose primary focal hyperhidrosis when the history is characteristic; the diagnosis rests on the pattern described in Recognize the Condition.^[4][2] Additional laboratory or radiologic investigation is reserved for patients whose history or examination suggests a secondary cause (see Risk Factors and Red Flags & Refer) — reflexive bloodwork in a patient with a classic primary presentation is not needed and can delay starting effective treatment.^[4] Ordinary sweating from heat, exercise, obesity, or anxiety in a proportionate context is not hyperhidrosis and does not need this diagnostic framework at all — the distinguishing feature is that hyperhidrosis is disproportionate to any thermoregulatory need.

Formal diagnostic criteria

A patient can be considered to have primary focal hyperhidrosis with focal, visible, excessive sweating of six months' duration or longer, plus at least two of the following: bilateral and relatively symmetric involvement; impairment of daily activities; a frequency of at least one episode per week; onset before age 25; a positive family history; and cessation of the focal sweating during sleep. Requiring more of these six criteria increases diagnostic specificity.^[2]

The Hyperhidrosis Disease Severity Scale (HDSS)

The HDSS is a simple, validated, single-item tool that drives the severity-based treatment algorithm used throughout this chapter. The patient selects the statement that best matches their experience for the affected site:^[4]

• Score 1 — sweating is never noticeable and never interferes with daily activities.
• Score 2 — sweating is tolerable but sometimes interferes with daily activities.
• Score 3 — sweating is barely tolerable and frequently interferes with daily activities.
• Score 4 — sweating is intolerable and always interferes with daily activities.

A score of 1 or 2 is considered mild-to-moderate disease and a score of 3 or 4 severe disease; a 1-point improvement in HDSS score correlates with roughly a 50% reduction in measured sweat production, and a 2-point improvement with roughly an 80% reduction — making the HDSS a genuinely useful proxy for treatment response, not just a subjective label.^[4]

Minor's starch-iodine test

A 3% to 5% iodine solution is applied to the area to be treated and allowed to dry, then starch powder is dusted over it; areas of active sweating turn a visible purple-black colour.^[2] This test is used primarily to delineate the precise area to be treated — particularly before botulinum toxin injection or topical therapy — rather than to establish severity, and the Canadian Hyperhidrosis Advisory Committee recommends performing it on every patient being considered for procedural treatment unless the treatment area has already been well documented from a previous session.^[4] Photographing the test result can also help objectively compare pre- and post-treatment response if a patient later reports an apparently inadequate effect.^[4]

Targeted investigations when a secondary cause is suspected

• Thyroid-stimulating hormone if hyperthyroidism is suspected from the history.^[2]
• Fasting glucose or HbA1c if diabetes is suspected or not previously diagnosed.^[2]
• A directed review for infection, fever, and constitutional symptoms (weight loss, night sweats) if these are present.^[6]
• A complete medication and substance-use history, specifically screening for SSRIs and other psychiatric medications, opioids (including recent dose reduction or discontinuation), and alcohol use.^[2][5]

• Reduce sweat production at the affected site(s) to a level the patient finds tolerable — full anhidrosis is not the goal, and is not achievable with most therapies.
• Meaningfully improve quality of life and reduce the psychosocial burden of the condition — the outcome that matters most to patients, and the one worth measuring (via the HDSS) at every visit.
• Identify and address any underlying secondary cause before committing a patient to long-term primary-hyperhidrosis therapy.
• Match treatment intensity, and the specific agent chosen, to both disease severity (HDSS score) and body site, following a staged, severity-based approach rather than a one-size-fits-all regimen.
• Minimize treatment-related adverse effects — skin irritation from topical agents, and the systemic anticholinergic burden of oral or topical anticholinergic therapy — while still achieving an adequate response.
• Set realistic expectations about duration of effect (particularly for botulinum toxin) and the likely need for maintenance or repeat treatment over time.

Step 1 — Topical aluminum chloride (all sites, all severities)

Aluminum chloride hexahydrate works mechanically: it forms a plug that occludes the eccrine sweat duct near the skin surface, reducing sweat delivery to the surface without destroying the gland itself.^[1] Correct application technique — genuinely the most common reason topical therapy appears to "not work" is incorrect application — apply to completely dry skin at bedtime, then wash off after 6 to 8 hours in the morning; use three to seven times per week until the patient becomes euhidrotic (sweat-normalized), then step down to maintenance treatment every one to three weeks.^[4] Applying it to already-sweaty or freshly washed/damp skin, or in the morning before daytime activity, both reduces efficacy and increases irritation, since the aluminum salt needs dry skin contact time to form the occlusive plug and is more easily rinsed or sweated off if applied to active sweat.^[4][1] Start at a lower concentration to minimize irritation and increase gradually only as needed: axillary and palmar disease typically starts around 10-12%, increasing up to 35% (axillary) or 50% (palmar) if needed; plantar disease typically starts around 20%, increasing up to 50%; craniofacial disease typically starts around 10%, increasing up to 20%.^[4] Euhidrosis at the higher end of these ranges often is not achieved until skin irritation becomes the practical limiting factor.^[4] Irritation management skin irritation and burning is the most common adverse effect, leading roughly 2-21% of patients to reduce concentration/frequency or discontinue entirely — counsel patients to reduce application frequency (for example, every second or third night) or step down concentration if irritation occurs, rather than stopping altogether, since tolerance to irritation often improves with continued use.^[4]

Step 2 — Topical glycopyrronium (anticholinergic) wipes, axillary/craniofacial

A newer prescription option, primarily for axillary disease glycopyrronium tosylate 2.4% cloths are applied once daily to clean, dry underarm skin — one individually packaged wipe treats both axillae — and work by locally blocking the muscarinic receptors that trigger sweat gland activation.^[7] They are FDA-approved in the United States (since 2018, for patients 9 years and older) but are not currently confirmed as Health Canada-approved; a pharmacist encountering this product on a prescription should verify its Canadian regulatory and supply status before dispensing rather than assuming automatic availability.^[7] Counsel on anticholinergic effects even with topical application, systemic absorption produces genuine anticholinergic effects in a meaningful minority of patients — dry mouth (reported in roughly 17-24% of patients), and less commonly mydriasis/blurred vision and urinary hesitancy — and patients should wash their hands thoroughly after application and avoid touching their eyes, since inadvertent transfer to the eye can cause unilateral pupil dilation and blurred vision.^[7]

Step 3 — Botulinum toxin injection (onabotulinumtoxinA)

Botulinum toxin A is the best-studied injectable therapy for focal hyperhidrosis and works by blocking acetylcholine release at the sympathetic cholinergic nerve terminals that innervate eccrine sweat glands, chemically interrupting the signal to sweat rather than affecting the gland's structure directly.^[1] OnabotulinumtoxinA is the only botulinum toxin product with a Health Canada-approved indication specifically for severe primary axillary hyperhidrosis; use at other sites (palmar, plantar, craniofacial) is well-established in the Canadian consensus algorithm but is technically off-label.^[4] Dosing is injected intradermally in a grid pattern across the affected area (confirmed by starch-iodine mapping): axillary dosing is roughly 1 U/cm² (3-4 U every 1.5-2 cm), typically 50-100 U per axilla; palmar dosing is 1.5-2 U/cm², typically around 100 U per palm (up to 150 U depending on response and surface area); plantar dosing is similarly 1.5-2 U/cm², typically around 150 U per sole (up to 200 U); craniofacial dosing is more variable and site-dependent, sometimes as low as 0.5 U/cm² for a very small area such as the upper lip, up to roughly 100 U depending on the area treated.^[4] Set expectations onset of benefit is not immediate, and effect is temporary — average duration of effect is approximately 7 months, with about 30% of patients experiencing benefit lasting longer than a year — so counsel patients up front that this is a repeat, not a one-time, treatment, typically re-dosed every 4 to 6 months for axillary disease as symptoms return.^[1][4] Common adverse effects injection-site pain and bruising are expected; transient weakness of the small intrinsic hand muscles is the most notable adverse effect with palmar injection, and patients should be counselled about temporary fine-motor impact.^[4]

Step 4 — Oral anticholinergics, for generalized or refractory primary disease

Reserved for disease not adequately controlled by the steps above, or for more generalized primary involvement across multiple sites — oral glycopyrrolate 1-2 mg up to three times daily, or oral oxybutynin (commonly 2.5-10 mg daily, titrated), are both used, alone or as an adjunct to topical/injectable therapy.^[4][2] These carry the standard, genuinely significant anticholinergic side-effect burden — dry mouth is extremely common (reported in a large majority of oxybutynin patients, and roughly a third to a half of glycopyrrolate patients), alongside blurred vision, constipation, urinary retention/hesitancy, and heat intolerance from reduced overall sweating capacity (a specific counseling point, since these patients are already living with an altered thermoregulatory pattern).^[2] Use caution, or avoid, in patients with narrow-angle glaucoma, significant benign prostatic hyperplasia/urinary retention, or a high overall anticholinergic burden from other medications.

• Iontophoresis (palmar and plantar disease) — the affected hands or feet are immersed in a shallow tray of tap water while a device delivers a low-intensity direct current (10-20 mA); treatments run 20-30 minutes, several times weekly, with the current direction switched halfway through each session, continued until the patient becomes euhidrotic (typically after 6-10 treatments), then stepped down to maintenance sessions every 1-4 weeks.^[4] It is considered first-line, alongside topical aluminum chloride and botulinum toxin, for palmar and plantar hyperhidrosis at any severity.^[4] Adding glycopyrrolate solution to the iontophoresis water can improve efficacy but increases the risk of systemic anticholinergic side effects.^[4]
• General hygiene and lifestyle measures — loose-fitting, breathable, moisture-wicking fabrics; clinical-strength antiperspirants (as distinct from cosmetic deodorants, which mask odour but do not reduce sweat) as an adjunct to prescription topical aluminum chloride; and avoiding known personal triggers (spicy food, caffeine, alcohol, situational anxiety) where a patient has identified them. These measures are reasonable adjuncts but are not a substitute for the staged pharmacologic ladder in a patient with a genuine primary hyperhidrosis diagnosis.
• Psychosocial support — given the substantial, validated quality-of-life burden of this condition (see Clinical Snapshot), explicitly acknowledging the emotional and social impact, rather than treating the complaint as trivial, is itself a meaningful part of care and can improve engagement with a staged treatment plan.^[4]
• Local surgical excision (axillary only) — subcutaneous curettage, tumescent liposuction, or direct excision of axillary sweat glands, done on an outpatient basis under local anesthesia; reserved for axillary disease that has not responded to two adequate trials of botulinum toxin, and carries a real risk of scarring and a prolonged recovery.^[4]
• Endoscopic thoracic sympathectomy (ETS) — surgical division or clipping of the relevant thoracic sympathetic ganglia; a genuinely effective but last-resort option, reserved for severe hyperhidrosis (typically palmar, sometimes craniofacial with prominent facial flushing) that has not responded to all other treatment options.^[4] The critical counseling point compensatory hyperhidrosis — new, often more bothersome excess sweating elsewhere on the body (commonly the trunk, back, or thighs) — is a well-documented, frequent complication, reported in roughly two-thirds of patients on long-term follow-up, and patients must be counselled on this trade-off and be willing to accept it before proceeding.^[4] Other reported complications include gustatory sweating, pneumothorax, and Horner's syndrome.^[4]

Children and adolescents

Primary focal hyperhidrosis characteristically begins in childhood or adolescence, so pediatric presentation is expected, not unusual, and deserves the same staged approach as in adults.^[3] Topical aluminum chloride is first-line and generally well tolerated, though children's skin may be more prone to irritation — start at the lower end of the concentration range. Glycopyrronium tosylate cloths are FDA-approved in the United States specifically down to age 9 for axillary use; botulinum toxin and oral anticholinergics are used in more disabling adolescent disease, but with more limited pediatric-specific dosing data than in adults, and generally by a clinician experienced in pediatric use.^[7]

Pregnancy and breastfeeding

Pregnancy itself is a common cause of new or worsened generalized sweating through hormonal/vasomotor changes — distinguish this physiologic pattern from a true exacerbation of pre-existing primary focal hyperhidrosis before escalating therapy. Topical aluminum chloride, with minimal systemic absorption, is a reasonable option to continue in pregnancy and breastfeeding. Oral anticholinergics (glycopyrrolate, oxybutynin) and botulinum toxin injection both have limited dedicated safety data in pregnancy and breastfeeding; discuss the specific risk-benefit with the prescriber case by case rather than reflexively continuing or stopping either.

Older adults

Oral and topical anticholinergic agents carry a disproportionate burden in older adults — confusion, constipation, urinary retention, and contribution to overall anticholinergic cognitive load — so favour topical aluminum chloride and, where indicated, botulinum toxin first, and use the lowest effective anticholinergic dose with closer monitoring if oral therapy is needed.

Narrow-angle glaucoma, benign prostatic hyperplasia, and urinary retention

Use caution or avoid oral or topical anticholinergic therapy (glycopyrrolate, oxybutynin, glycopyrronium wipes) in patients with narrow-angle glaucoma or significant benign prostatic hyperplasia/urinary retention, given the class's anticholinergic mechanism — favour topical aluminum chloride or botulinum toxin instead in these patients.

Reassess the HDSS score at the affected site at every follow-up visit — it is the same simple, validated tool used to guide initial therapy selection and remains the most practical way to track real treatment response.^[4] For topical aluminum chloride and oral anticholinergics, a formal treatment-response check at one month is reasonable: no meaningful change in HDSS score, or intolerable side effects at that point, defines treatment failure and should prompt escalation rather than an indefinitely continued trial.^[4]

For botulinum toxin, track the interval since the last injection and the patient's own report of when sweating returns to a bothersome level (rather than a fixed calendar date) — re-treatment is appropriate once HDSS returns to 3 or 4, generally no sooner than the minimum interval established in clinical trials, and typically averaging every 4 to 6 months for axillary disease.^[4] If a patient reports poor or short-lived benefit, reassess for a missed sub-area of the treated site (repeat starch-iodine mapping and compare against pretreatment photos if available) before concluding the treatment itself has failed.^[4]

For any patient on an oral or topical anticholinergic, periodically ask about dry mouth, blurred vision, constipation, and urinary symptoms, and reconfirm there is no new contraindication (for example, a new glaucoma or BPH diagnosis). For a patient managed initially as primary hyperhidrosis, stay alert at every visit for a change in pattern — new sleep involvement, new systemic symptoms, or a shift from focal to generalized sweating — that should prompt reconsideration of a secondary cause (see Red Flags & Refer).

1. Topical aluminum chloride with no improvement (or intolerable irritation) after a full one-month trial with confirmed correct technique (dry skin, bedtime application): move to the next step for that site and severity — botulinum toxin, iontophoresis (palmar/plantar), or topical glycopyrronium wipes (axillary) — rather than extending the trial indefinitely or simply increasing concentration further.^[4]
2. Apparent botulinum toxin failure, or a much shorter-than-expected duration of benefit: before assuming true treatment failure, reassess injection technique and coverage — repeat the starch-iodine test to confirm no sub-area was missed, and compare against pretreatment photos if available. A second round of injections at the same or a slightly higher dose to the confirmed area is reasonable before declaring failure.^[4]
3. Failure of topical therapy or botulinum toxin alone (axillary, palmar, or plantar): consider combining the two — using topical aluminum chloride and botulinum toxin together, or adding topical therapy to iontophoresis, is a recognized next step for severe disease not controlled by either alone.^[4]
4. Failure of topical therapy, botulinum toxin, and/or iontophoresis in combination: add oral medication (glycopyrrolate or oxybutynin) as an adjunct or trial it alone, watching closely for the class's anticholinergic side-effect burden.^[4]
5. Severe axillary disease refractory to all of the above: refer for local surgical treatment (excision, curettage, or liposuction of the axillary sweat glands).^[4]
6. Severe palmar (or craniofacial with prominent flushing) disease refractory to all other options: refer for endoscopic thoracic sympathectomy assessment, with explicit, documented counseling on the real risk of compensatory hyperhidrosis before the patient proceeds.^[4]
7. A patient whose presentation shifts during treatment — new sleep involvement, new systemic symptoms, or a pattern that no longer fits primary focal disease — should have therapy paused for reassessment and a secondary-cause workup, rather than being escalated further along the primary-hyperhidrosis ladder.

• Dismissing hyperhidrosis as a purely cosmetic concern and offering only reassurance — it has a real, validated impact on quality of life and deserves a genuine, staged treatment plan.
• Applying topical aluminum chloride to damp or freshly washed skin, or in the morning rather than at bedtime — this is one of the most common reasons topical therapy appears ineffective, and simply correcting technique can salvage a trial that looked like a failure.
• Declaring topical therapy a failure before a full one-month trial at an adequate concentration and correct technique.
• Assuming botulinum toxin has "stopped working" without first checking whether the entire affected area was actually covered — a missed sub-area, confirmed with a repeat starch-iodine test, is a common and correctable cause of apparent failure.
• Starting an oral or topical anticholinergic without asking about glaucoma, benign prostatic hyperplasia/urinary retention, or an already-high anticholinergic burden from other medications, particularly in older adults.
• Treating new-onset generalized hyperhidrosis, or hyperhidrosis with sleep involvement or systemic symptoms, as though it were primary focal disease rather than pursuing a secondary-cause workup first.
• Assuming any topical glycopyrronium/anticholinergic wipe product encountered is automatically available and funded in Canada exactly as it is in the United States, without verifying its actual Canadian regulatory and supply status.
• Recommending or proceeding to endoscopic thoracic sympathectomy without first exhausting topical, injectable, and oral options, or without clearly counseling the patient on the real risk of compensatory hyperhidrosis beforehand.
• Confusing a cosmetic deodorant (which only masks odour) with a clinical-strength antiperspirant or prescription aluminum chloride product (which actually reduces sweat volume) when counseling a patient on realistic expectations.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Topical Agents — First-Line, All Sites and Severities

Correct technique (dry skin, bedtime application) matters as much as the agent chosen — see Choose Initial Treatment.

Oral Anticholinergics — Generalized or Refractory Primary Hyperhidrosis

Second-line/adjunct to topical and injectable therapy; titrate to the lowest effective dose given the genuine anticholinergic burden of this class.

Botulinum Toxin — Injectable Therapy by Body Site

Injected intradermally across the affected area, mapped with the minor's starch-iodine test. OnabotulinumtoxinA is the only botulinum toxin product with a Health Canada-approved hyperhidrosis indication (axillary); other sites are established but off-label, and other botulinum toxin products (abobotulinumtoxinA, incobotulinumtoxinA, and others) do not carry a Canadian hyperhidrosis indication.